NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
13F holders, Q3 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- +6 vs. Q2 2023
- Shares held
- 50.2M
- +1.34M (+2.8%) vs. Q2 2023
- Total value
- $464.1M
- −$116.5M (−20.1%) vs. Q2 2023
- New holders
- 9
- 9 more added
- Sold out
- 3
- 6 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 194 | $4.13B |
| Q1 2026 | 171 | $3.96B |
| Q4 2025 | 187 | $4.19B |
| Q3 2025 | 137 | $3.43B |
| Q2 2025 | 131 | $2.11B |
| Q1 2025 | 126 | $2.28B |
| Q4 2024 | 131 | $2.53B |
| Q3 2024 | 100 | $1.28B |
| Q2 2024 | 90 | $1.38B |
| Q1 2024 | 76 | $1.71B |
| Q4 2023 | 32 | $691.4M |
| Q3 2023 | 35 | $464.1M |
| Q2 2023 | 29 | $580.6M |
| Q1 2023 | 19 | $444.9M |
| Q4 2022 | 14 | $362.2M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12,131,705 | $112.2M | 7.46% | +1,259,902+11.6% | Added |
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | $96.9M | 10.83% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 9,000,000 | $83.3M | 1.64% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 8,024,565 | $74.2M | 0.30% | +1,500,000+23.0% | Added |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | $26.5M | 8.47% | 00.0% | Unchanged |
| BVF Inc | 1,521,948 | $14.1M | 0.38% | 00.0% | Unchanged |
| GMT Capital Corp | 1,383,800 | $12.8M | 0.48% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,200,000 | $11.1M | 0.03% | 00.0% | Unchanged |
| Millennium Management LLC | 1,044,784 | $9.66M | 0.01% | +671,232+179.7% | Added |
| Eversept Partners, LP | 660,618 | $6.11M | 0.68% | −31,751−4.6% | Reduced |
| Ensign Peak Advisors, Inc | 437,733 | $4.05M | 0.01% | −4,223−1.0% | Reduced |
| Janus Henderson Group PLC | 434,912 | $3.97M | 0.00% | +434,912 | New |
| AXA S.A. | 283,015 | $2.62M | 0.01% | +58,664+26.1% | Added |
| Parkman Healthcare Partners LLC | 249,024 | $2.30M | 0.42% | +9,973+4.2% | Added |
| Affinity Asset Advisors, LLC | 125,000 | $1.16M | 0.38% | +25,000+25.0% | Added |
| Schonfeld Strategic Advisors LLC | 64,700 | $598.5K | 0.01% | +7,400+12.9% | Added |
| UBS Oconnor LLC | 45,000 | $416.3K | 0.01% | +45,000 | New |
| Alyeska Investment Group, L.P. | 44,432 | $411.0K | 0.00% | −85,115−65.7% | Reduced |
| Geode Capital Management, LLC | 41,808 | $386.7K | 0.00% | +16,040+62.2% | Added |
| Citadel Advisors LLC | 31,397 | $290.4K | 0.00% | +31,397 | New |
| Maven Securities LTD | 25,000 | $231.3K | 0.03% | 00.0% | Unchanged |
| BlackRock Inc. | 22,941 | $212.2K | 0.00% | +22,941 | New |
| Parkwood LLC | 20,209 | $187.0K | 0.03% | +20,209 | New |
| CIBC Private Wealth Group, LLC | 13,000 | $120.3K | 0.00% | +13,000 | New |
| Marshall Wace, LLP | 10,164 | $94.0K | 0.00% | −15,197−59.9% | Reduced |
| Venture Visionary Partners LLC | 10,000 | $92.5K | 0.01% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 2,925 | $27.1K | 0.00% | +2,925 | New |
| JPMorgan Chase & Co | 2,622 | $24.3K | 0.00% | −8,841−77.1% | Reduced |
| Morgan Stanley | 1,702 | $15.7K | 0.00% | +894+110.6% | Added |
| Royal Bank of Canada | 1,000 | $9.00K | 0.00% | +1,000 | New |
| Barclays PLC | 513 | $4.75K | 0.00% | +513 | New |
| Cutler Group LP | 500 | $4.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 300 | $2.77K | 0.00% | 00.0% | Unchanged |
| Atticus Wealth Management, LLC | 100 | $925 | 0.00% | −66−39.8% | Reduced |
| DuPont Capital Management Corp | 1 | $9 | 0.00% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −2,535,723−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −95,000−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −183−100.0% | Sold out |